SVB Leerink reiterates Sarepta Therapeutics [SRPT] rating to Outperform and sets new price target at $125
SVB Leerink maintained its Sarepta Therapeutics [SRPT] rating to the equivalent of Outperform but changed the price target to $125.0 from $197, in a research note dated 2021-01-08. That figure represents around a -26.01% premium from where the company’s shares closed on Thursday. Some new analysts also started their coverage, with UBS’s analysts assigning the […]
